A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703

NCT01982747 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: MGN-Placebo
DRUG: Placebo-MGN

Sponsor

Mologen AG